secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001193125-24-040726
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharmaceuticals names Philip Johnson as CFO, effective March 1, 2024
-------------------------------------------------------------------------

- Philip Johnson appointed EVP and CFO; succeeds Renée Galá who became President and COO in October 2023.
- Johnson previously served as Group VP of Finance, Treasurer at Eli Lilly; over 35 years financial experience.
- Annual base salary $700,000; target bonus 65% of salary; signing bonus $150,000.
- New hire equity grant approximate value $4M, equal mix of restricted stock units and performance stock units.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524040726/0001193125-24-040726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524040726/d579255d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-040726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer